Brief: Rosetta Genomics and Biocept advance collaboration to proof-of-concept studies aimed at microrna profiling of circulating tumor cells to enhance lung cancer diagnosis
14/12/2015 13:00
Dec 14 (Reuters) - Rosetta Genomics Ltd ROSG.O : * Rosetta Genomics and Biocept advance collaboration to proof-of-concept studies aimed at microrna profiling of circulating tumor cells to enhance lung cancer diagnosis * Says Rosetta and Biocept will test for markers currently offered by Rosetta, as well as pursue new markers * Source text for Eikon ID:nBw24HJwFa * Further company coverage ROSG.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Rosetta Genomics
See all newsBrief: Interpace Diagnostics Acquires Select Assets Of Rosetta Genomics Out Of Bankruptcy
Brief: Stockholders Approve Genoptix Acquisition Of Rosetta Genomics
Brief: Rosetta Genomics Announces Shareholder Approval Of Merger With Genoptix
Brief: Sabby Management Buys 105,361 ADR Shares Of Rosetta Genomics
Brief: Genoptix Announces Termination Of Merger Agreement With Rosetta Genomics